March 20, 2020 / 11:08 AM / 18 days ago

BRIEF-Sorrento Develops STI-4398 For Potential Prevention And Treatment Of COVID-19

March 20 (Reuters) - Sorrento Therapeutics Inc:

* SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

* SORRENTO THERAPEUTICS INC - STI-4398 IS IN CGMP CELL LINE DEVELOPMENT STAGE

* SORRENTO - STI-4398 COULD BE READY FOR LARGE-SCALE PRODUCTION IN CGMP FACILITIES IN SAN DIEGO FOR HUMAN CLINICAL TRIALS UPON RECEIPT OF APPROVALS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below